NASDAQ:FBIO • US34960Q3074
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for FORTRESS BIOTECH INC (FBIO).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-02-23 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-08-21 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-03-11 | Roth MKM | Reiterate | Buy -> Buy |
| 2024-11-18 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-07-19 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-06-20 | Cantor Fitzgerald | Reiterate | Overweight |
| 2024-05-16 | Roth MKM | Reiterate | Buy -> Buy |
| 2024-03-19 | Alliance Global Partners | Initiate | Buy |
| 2024-03-15 | Roth MKM | Reiterate | Buy |
| 2023-11-29 | Roth MKM | Maintains | Buy -> Buy |
| 2023-08-15 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2023-05-16 | Cantor Fitzgerald | Maintains | Overweight -> Overweight |
| 2023-04-06 | Benchmark | Reiterate | Speculative Buy |
| 2022-08-04 | Ladenburg Thalmann | Initiate | Buy |
| 2022-07-14 | B. Riley Securities | Maintains | Buy |
| 2021-04-20 | Roth Capital | Maintains | Buy |
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | ||
|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 84.513M 11.58% | 57.675M -31.76% | 63.262M 9.69% | 98.194M 55.22% | 138.01M 40.55% | 680.14M 392.82% | 721.75M 6.12% | 736.44M 2.04% | |
| EBITDA YoY % growth | -133.245M 32.08% | -106.776M 19.86% | -65.56M 38.60% | -34.17M 47.88% | -12.342M 63.88% | N/A | N/A | N/A | |
| EBIT YoY % growth | -139.242M 31.60% | -111.24M 20.11% | -70.221M 36.87% | -28.18M 59.87% | -12.342M 56.20% | 180.74M 1,564.43% | 195.84M 8.35% | 188.5M -3.75% | |
| Operating Margin | -164.76% | -192.87% | -111.00% | -28.70% | -8.94% | 26.57% | 27.13% | 25.60% | |
| EPS YoY % growth | -8.97 38.18% | -3.27 63.55% | -0.88 73.09% | 0.01 101.16% | 1.54 15,000.00% | N/A | N/A | N/A |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|
| EPS Q2Q % growth | -0.22 53.25% | -0.19 61.24% | -0.16 -248.36% | -0.14 -1,328.00% |
| Revenue Q2Q % growth | 16.665M 26.84% | 19.801M 20.64% | 22.938M 30.10% | 23.97M 49.08% |
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -5.756M 74.21% | -4.685M 87.16% | -3.043M 55.33% | -2.893M 39.60% |
All data in USD
8 analysts have analysed FBIO and the average price target is 10.97 USD. This implies a price increase of 370.6% is expected in the next year compared to the current price of 2.33.
FORTRESS BIOTECH INC (FBIO) will report earnings on 2026-05-13.
The consensus EPS estimate for the next earnings of FORTRESS BIOTECH INC (FBIO) is -0.22 USD and the consensus revenue estimate is 16.66M USD.
The number of analysts covering FORTRESS BIOTECH INC (FBIO) is 8.